Emmaus Life Sciences Q2 revenue soars on licensing deal

Emmaus Life Sciences

14/08/2026 21:20

Overview
US biopharmaceutical firm's Q2 revenue rose 124% yr/yr, driven by NIT license agreement
Company reduced operating expenses following sales force transfer to NeoImmuneTech
Emmaus posted net income for Q2, reversing a loss from the prior year period

Outlook
Company did not provide specific guidance for the current or future periods in the press release

Result Drivers
NIT LICENSE REVENUE - Revenue growth driven by upfront payment and royalties from NeoImmuneTech license agreement
LOWER OPERATING EXPENSES - Operating costs fell due to transfer of sales force to NeoImmuneTech

Company press release: ID:nBwcczyL4a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Revenues
 
$6.32 mln
 
Q2 EPS
 
$0.02
 
Q2 Net Income
 
$1.34 mln
 
Q2 Gross Profit
 
$5.97 mln
 
Q2 Income from Operations
 
$3.79 mln
 
Q2 Operating Expenses
 
$2.18 mln
 

Reuters Recommended Reads
Aug 13 - MeiraGTx Q2 revenue jumps on Reogen license revenue
Aug 13 - Rani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Aug 13 - Eton Pharmaceuticals Q2 adjusted EPS beats estimates, revenue up 99% on HEMANGEOL relaunch

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)